Product Development

Female cancers that affect the breast and ovary share two common traits - they are highly curable when detected in the early stages of development, and they are highly lethal when caught late. Unfortunately, today’s health care environment offers no simple, office-based tests designed to help identify patients at risk for these conditions.

For breast cancer, of course, the mammogram is generally regarded as the best means of early detection. Mammograms, however, usually require a referral and a separate visit to a radiology center - and can potentially miss over 30 percent of breast cancers. And for cancers of the reproductive organs, the Pap smear is only indicated for the early detection of cervical cancer. Meanwhile, more than 25,000 cases of ovarian cancer are diagnosed a year, usually at the stage where they are symptomatic. As a result, the overall mortality rate for ovarian cancer is currently between 53 and 75 percent.

Lifeline Biotechnologies^TM has made a substantial commitment in the scientific and intellectual capital needed to address these two unanswered needs. We recognize that breakthroughs in these markets will bring substantial reward - from both a business and clinical perspective.